PubMed 6
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), which were initially approved for the treatment of type 2 diabetes (T2D) and obesity, have cardiovascular benefits that extend beyond glycaemic control
Second, refunds are uncommon: prescription items are final sale, consults and labs are nonrefundable, and multimonth savings plans billed monthly cannot be canceled until the full term is paid
Building sustainable nutrition and lifestyle habits remains foundational to lasting metabolic health, whether someone chooses to take a GLP-1 or not
11 While GLP-1 coverage for obesity is one option, employers can also explore offering medical nutrition therapy, psychological and behavioral support or surgical interventions to improve worker health without the pharmacotherapy expense
Short- and rapid-acting insulin can be added to basal insulin to intensify therapy to address prandial blood glucose levels